3 assets in Wild Type ATTR Amyloidosis

Therapeutic assets addressing Wild Type ATTR Amyloidosis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Dobutrex Wild Type ATTR Amyloidosis	Steen Hvitfeldt Poulsen	P1/2	NR ()
nnc6019-0001 Wild Type ATTR Amyloidosis	Novo Nordisk A/S	P3	NR ()
Patisiran Wild Type ATTR Amyloidosis	Austin Neuromuscular Center	Early P1	NR ()